• DNDi logo
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • COVID-19
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • HAT Platform
      • HELP Helminth Elimination Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Global Headquarters
      • DNDi DRC
      • DNDi East Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi Southern Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
DNDi logo
  • DNDi logo
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • COVID-19
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • HAT Platform
      • HELP Helminth Elimination Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Global Headquarters
      • DNDi DRC
      • DNDi East Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi Southern Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
Home > Events

COVID-19 therapeutics in resource-constrained settings: Where are we and what do we need?

27 January 2022, 10 AM Rio / 4 PM Nairobi / 8 PM Bangkok

Online webinar

Share on twitter
Share on facebook
Share on linkedin
Share on email
Share on print

To date, the few medications with proven effectiveness in COVID-19 are appropriate primarily for the treatment of severely ill, hospitalized patients in well-resourced healthcare settings. WHO recommends the use of monoclonal antibody treatment for people with early-stage COVID-19, but these treatments too are expensive and complex to use in resource-constrained settings. No proven medications for uncomplicated COVID-19 are widely available in low- and middle-income countries.

So where are we today with new and emerging therapeutics that would be both effective and affordable in preventing the progression of mild or moderate COVID-19 and thereby prevent hospitalization? A couple of promising treatments have emerged recently, with early efforts underway to make these drugs more available than COVID-19 vaccines have been. What are the current research priorities, and do current efforts meet the needs?

The COVID-19 Clinical Research Coalition is hosting a webinar that will:

  • Summarize the therapeutics development landscape for COVID-19
  • Discuss the challenges in prioritizing drugs to be studied
  • Assess the treatment needs in low- and middle-income countries
  • Discuss the challenges of ensuring affordable access to new therapeutics, and what can be done now to ensure equitable access globally to proven medicines.

Watch the recording

Agenda

Welcome and introduction
Patricia García, Cayetano Heredia University, Peru
Where are we now with COVID-19 therapeutics? A Latin American perspective
Ludovic Reveiz, PAHO, USA
Where are we now with COVID-19 therapeutics? A South African perspective
Jeremy Nel, University of the Witwatersrand, South Africa
Practical realities in COVID-19 treatment now. What is needed?
Samba Sow, Centre for Vaccine Development, Mali
Impact of recent clinical trial results on current research priorities
Nathalie Strub-Wourgaft, COVID-19 Response and Pandemic Preparedness Director, DNDi, Switzerland
If medicines work, how can we ensure people get them?
Leena Menghaney, MSF Access Campaign, India
Roundtable and Q&A

Moderators: Podjanee Jittamala, Faculty of Tropical Medicine, Mahidol University, Thailand, and Nick White, Mahidol-Oxford Research Unit, Thailand, and Chair of DNDi‘s Scientific Advisory Committee
COVID-19

Other events

Loading...
28 June - 1 July 2022

Singapore

Global Health Security Conference 2022

7-10 June 2022

Virtual event

World Hepatitis Summit 2022

25 May 2022

Davos, Switzerland

An SDG target we can reach: Financing viral hepatitis elimination

16 May 2022, 1:00 PM Paris

Paris, France and online

Gouverner en temps de pandémie: Faire des produits de santé un bien commun mondial

See all

Stay connected

Get our latest news, personal stories, research articles, and job opportunities. 

DNDi logo
Facebook-f
Twitter
Instagram
Linkedin-in
Youtube
International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

Learn more

  • Diseases
  • R&D portfolio
  • Policy advocacy

Get in touch

  • Our offices
  • Contact us
  • Integrity Line

Support us

  • Donate
  • Subscribe to eNews

Work with us

  • Join research networks
  • Jobs
  • RFPs
  • Terms of Use   
  •   Acceptable Use Policy   
  •   Privacy Policy   
  •   Cookie Policy   
  •   Our policies   

  • Except for images, films and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Switzerland License   
We use cookies to track our audience and improve our content. By continuing to browse our website, you are agreeing to our use of cookies.CLOSECOOKIE POLICY